Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Proto

Showing results (481-490 of 595) with videos related to

Pageof 60
Sort By:
Journal of Personalized Medicine|June 2, 2021
Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase InhibitorsMario Occhipinti, Marta Brambilla, Giulia Galli, et al.
Future Oncology (London, England)|June 20, 2022
Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapyEmma Zattarin, Sara Manglaviti, Giulia Apollonio, et al.
Clinical Lung Cancer|February 23, 2021
Recent Advances in the Management of Typical and Atypical Lung CarcinoidsNatalie Prinzi, Roberta Elisa Rossi, Claudia Proto, et al.
JTO Clinical and Research Reports|September 25, 2024
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 StudyJoel W Neal, Armando Santoro, Maria Gonzalez-Cao, et al.
Tumori|June 4, 2026
Alectinib and gastrointestinal perforation in ALK-rearranged non-small cell lung cancer: A case seriesMargherita Piccinelli, Raffaele Squitieri, Rebecca Romanò, et al.
Exploration of Targeted Anti-Tumor Therapy|November 7, 2022
Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samplesIolanda Capone, Fabio Bozzi, Gian Paolo Dagrada, et al.
Frontiers in Oncology|April 25, 2022
Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary ModelJacopo Azzollini, Andrea Vingiani, Luca Agnelli, et al.
Acta Oncologica (Stockholm, Sweden)|April 22, 2024
Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter studyRosalba Miceli, Hanna Eriksson, Giuseppe Lo Russo, et al.
Oncogene|September 15, 2010
BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patientsD D De Carvalho, R Binato, W O Pereira, et al.
Leukemia Research|April 20, 2006
PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphomaRodrigo Proto-Siqueira, Lorena L Figueiredo-Pontes, Rodrigo A Panepucci, et al.
Pageof 60

Showing results (481-490 of 595) with videos related to

Sort By:
Pageof 60
Journal of Personalized Medicine|June 2, 2021
Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase InhibitorsMario Occhipinti, Marta Brambilla, Giulia Galli, et al.
Future Oncology (London, England)|June 20, 2022
Prognostic role of neutrophil-to-lymphocyte ratio and EPSILoN score in advanced non-small-cell lung cancer patients treated with first-line chemo-immunotherapyEmma Zattarin, Sara Manglaviti, Giulia Apollonio, et al.
Clinical Lung Cancer|February 23, 2021
Recent Advances in the Management of Typical and Atypical Lung CarcinoidsNatalie Prinzi, Roberta Elisa Rossi, Claudia Proto, et al.
JTO Clinical and Research Reports|September 25, 2024
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 StudyJoel W Neal, Armando Santoro, Maria Gonzalez-Cao, et al.
Tumori|June 4, 2026
Alectinib and gastrointestinal perforation in ALK-rearranged non-small cell lung cancer: A case seriesMargherita Piccinelli, Raffaele Squitieri, Rebecca Romanò, et al.
Exploration of Targeted Anti-Tumor Therapy|November 7, 2022
Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samplesIolanda Capone, Fabio Bozzi, Gian Paolo Dagrada, et al.
Frontiers in Oncology|April 25, 2022
Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary ModelJacopo Azzollini, Andrea Vingiani, Luca Agnelli, et al.
Acta Oncologica (Stockholm, Sweden)|April 22, 2024
Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter studyRosalba Miceli, Hanna Eriksson, Giuseppe Lo Russo, et al.
Oncogene|September 15, 2010
BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patientsD D De Carvalho, R Binato, W O Pereira, et al.
Leukemia Research|April 20, 2006
PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphomaRodrigo Proto-Siqueira, Lorena L Figueiredo-Pontes, Rodrigo A Panepucci, et al.
Pageof 60